Regeneron Pharmaceuticals EBIT

The latest EBIT for REGN is $5B as of September 2026. That compares with $4.6B in the prior-year period — up 7.5% year over year. That is below the Healthcare sector average of $2T. Investors often review this figure alongside Regeneron Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, REGN's EBIT moved from $4.6B to $5B — a 7.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Regeneron Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, REGN currently prints $5B for EBIT, while the sector average sits near $2T. That is roughly 99.7% below the sector mean. Large gaps often invite a closer look at Regeneron Pharmaceuticals's growth, margins, and balance sheet.

A EBIT figure of $5B for REGN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $2T. Explore the charts below for those layers of context.

After noting REGN's EBIT ($5B), review year-over-year change from $4.6B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.